Literature DB >> 34499725

Representativeness of Participants Eligible to Be Enrolled in Clinical Trials of Aducanumab for Alzheimer Disease Compared With Medicare Beneficiaries With Alzheimer Disease and Mild Cognitive Impairment.

Timothy S Anderson1, John Z Ayanian2,3, Jeffrey Souza4, Bruce E Landon4.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34499725      PMCID: PMC8430904          DOI: 10.1001/jama.2021.15286

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   157.335


× No keyword cloud information.
  9 in total

Review 1.  The Current Landscape of Prevention Trials in Dementia.

Authors:  Jonathan Lee; Rebecca Sitra Howard; Lon S Schneider
Journal:  Neurotherapeutics       Date:  2022-05-19       Impact factor: 6.088

2.  Aducanumab Use in Symptomatic Alzheimer Disease Evidence in Focus: A Report of the AAN Guidelines Subcommittee.

Authors:  Gregory S Day; Nikolaos Scarmeas; Richard Dubinsky; Katherine Coerver; Anitra Mostacero; Brooks West; Scott R Wessels; Melissa J Armstrong
Journal:  Neurology       Date:  2022-02-23       Impact factor: 11.800

Review 3.  Heterogeneity in Alzheimer's Disease Diagnosis and Progression Rates: Implications for Therapeutic Trials.

Authors:  Ranjan Duara; Warren Barker
Journal:  Neurotherapeutics       Date:  2022-01-27       Impact factor: 6.088

4.  Key recommendations from the 2021 "inclusion of older adults in clinical research" workshop.

Authors:  Darina V Petrovsky; Lan N Ðoàn; Maria Loizos; Rachel O'Conor; Micah Prochaska; Mazie Tsang; Rachel Hopman-Droste; Tara C Klinedinst; Aarti Mathur; Karen Bandeen-Roche; Odette van der Willik; Stephen B Kritchevsky
Journal:  J Clin Transl Sci       Date:  2022-01-07

Review 5.  Blood-brain barrier leakage in Alzheimer's disease: From discovery to clinical relevance.

Authors:  Geetika Nehra; Bjoern Bauer; Anika M S Hartz
Journal:  Pharmacol Ther       Date:  2022-01-30       Impact factor: 13.400

Review 6.  Aducanumab Therapy to Treat Alzheimer's Disease: A Narrative Review.

Authors:  Semira Abdi Beshir; A M Aadithsoorya; Affana Parveen; Sheron Sir Loon Goh; Nadia Hussain; Vineetha Bharathan Menon
Journal:  Int J Alzheimers Dis       Date:  2022-03-09

7.  Use of Extrapolation in New Drug Approvals by the US Food and Drug Administration.

Authors:  Daniel Feldman; Jerry Avorn; Aaron S Kesselheim
Journal:  JAMA Netw Open       Date:  2022-04-01

Review 8.  Exosomes in Age-Related Cognitive Decline: Mechanistic Insights and Improving Outcomes.

Authors:  Michael R Duggan; Anne Lu; Thomas C Foster; Mathieu Wimmer; Vinay Parikh
Journal:  Front Aging Neurosci       Date:  2022-03-01       Impact factor: 5.750

9.  mRNA Vaccines Against SARS-CoV-2 Variants Delivered by Lipid Nanoparticles Based on Novel Ionizable Lipids.

Authors:  Kepan Chen; Na Fan; Hai Huang; Xin Jiang; Shugang Qin; Wen Xiao; Qian Zheng; Yupei Zhang; Xing Duan; Zeyi Qin; Yongmei Liu; Jun Zeng; Yuquan Wei; Xiangrong Song
Journal:  Adv Funct Mater       Date:  2022-07-19       Impact factor: 19.924

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.